Business Description
Eiger BioPharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US28249U1051
Description
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.17 | |||||
| Equity-to-Asset | -0.01 | |||||
| Debt-to-Equity | -38.52 | |||||
| Debt-to-EBITDA | -0.8 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -24.3 | |||||
| Beneish M-Score | -3.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10.4 | |||||
| 3-Year EPS without NRI Growth Rate | 9.8 | |||||
| 3-Year FCF Growth Rate | 9.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.04 | |||||
| 9-Day RSI | 35.2 | |||||
| 14-Day RSI | 34.9 | |||||
| 6-1 Month Momentum % | 99.8 | |||||
| 12-1 Month Momentum % | 9.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.01 | |||||
| Quick Ratio | 1.01 | |||||
| Cash Ratio | 0.6 | |||||
| Days Inventory | 3172.18 | |||||
| Days Sales Outstanding | 92.9 | |||||
| Days Payable | 5199.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.4 | |||||
| Shareholder Yield % | -22.84 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.82 | |||||
| Operating Margin % | -532.17 | |||||
| Net Margin % | -585.78 | |||||
| FCF Margin % | -1137.37 | |||||
| ROA % | -69.97 | |||||
| ROIC % | -150.65 | |||||
| ROC (Joel Greenblatt) % | -3895.12 | |||||
| ROCE % | -168.85 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.91 | |||||
| EV-to-EBIT | -0.23 | |||||
| EV-to-EBITDA | -0.23 | |||||
| EV-to-Revenue | 1.2 | |||||
| EV-to-FCF | -0.11 | |||||
| Earnings Yield (Greenblatt) % | -434.78 | |||||
| FCF Yield % | -594.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:EIGRQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eiger BioPharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.575 | ||
| EPS (TTM) ($) | -26.128 | ||
| Beta | 0 | ||
| Volatility % | 468.35 | ||
| 14-Day RSI | 34.9 | ||
| 14-Day ATR ($) | 0.847086 | ||
| 20-Day SMA ($) | 8.525 | ||
| 12-1 Month Momentum % | 9.29 | ||
| 52-Week Range ($) | 1.1 - 16 | ||
| Shares Outstanding (Mil) | 1.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eiger BioPharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eiger BioPharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eiger BioPharmaceuticals Inc Frequently Asked Questions
What is Eiger BioPharmaceuticals Inc(EIGRQ)'s stock price today?
The current price of EIGRQ is $8.50. The 52 week high of EIGRQ is $16.00 and 52 week low is $1.10.
When is next earnings date of Eiger BioPharmaceuticals Inc(EIGRQ)?
The next earnings date of Eiger BioPharmaceuticals Inc(EIGRQ) is 2025-03-01 Est..
Does Eiger BioPharmaceuticals Inc(EIGRQ) pay dividends? If so, how much?
Eiger BioPharmaceuticals Inc(EIGRQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers